RA Capital Management L.P. Makes New $11.25 Million Investment in Monopar Therapeutics Inc. (NASDAQ:MNPR)

RA Capital Management L.P. acquired a new stake in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 511,207 shares of the company's stock, valued at approximately $11,247,000. RA Capital Management L.P. owned 8.38% of Monopar Therapeutics at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth $45,000. Geode Capital Management LLC grew its position in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after buying an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics in the fourth quarter valued at $2,861,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in Monopar Therapeutics during the 4th quarter valued at $13,182,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Stock Down 5.1 %

MNPR traded down $2.22 during trading on Tuesday, reaching $41.15. The stock had a trading volume of 5,867 shares, compared to its average volume of 42,266. Monopar Therapeutics Inc. has a 1-year low of $1.72 and a 1-year high of $54.30. The stock has a 50 day moving average of $36.16 and a two-hundred day moving average of $30.37. The firm has a market capitalization of $251.60 million, a price-to-earnings ratio of -21.05 and a beta of 1.11.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87). On average, research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the transaction, the insider now directly owns 822,255 shares in the company, valued at $28,778,925. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 34.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Piper Sandler reiterated an "overweight" rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.